{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:27:19Z","timestamp":1791235639138,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.euf.2020.06.013","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T17:00:25Z","timestamp":1593450025000},"page":"1448-1467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3660-110X","authenticated-orcid":false,"given":"Mohammad","family":"Abrar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Pindoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3712-9460","authenticated-orcid":false,"given":"Sachin","family":"Malde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9480-8972","authenticated-orcid":false,"given":"Michael","family":"Chancellor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"DeRidder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4679-0506","authenticated-orcid":false,"given":"Arun","family":"Sahai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2020.06.013_bib0005","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1464-410X.2009.08777.x","article-title":"The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?","volume":"104","author":"Chapple","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2020.06.013_bib0010","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.juro.2010.02.009","article-title":"Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature","volume":"183","author":"Anger","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2020.06.013_bib0015","article-title":"Botulinum toxin injections for adults with overactive bladder syndrome","volume":"12","author":"Duthie","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.euf.2020.06.013_bib0020","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1159\/000351037","article-title":"Botulinum toxin-A injections for idiopathic overactive bladder: a systematic review and meta-analysis","volume":"91","author":"Cui","year":"2013","journal-title":"Urol Int"},{"key":"10.1016\/j.euf.2020.06.013_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147137","article-title":"Factors associated with therapeutic efficacy of intravesical onabotulinumtoxinA injection for overactive bladder syndrome","volume":"11","author":"Hsiao","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.euf.2020.06.013_bib0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.juro.2008.03.028","article-title":"Refractory idiopathic urge urinary incontinence and botulinum A injection","volume":"180","author":"Brubaker","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2020.06.013_bib0035","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2020.06.013_bib0040","unstructured":"Howick J, Chalmers I, Glasziou P, et al. The Oxford levels of evidence 2. https:\/\/www.cebm.net\/index.aspx?o=5653."},{"key":"10.1016\/j.euf.2020.06.013_bib0045","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.euf.2020.06.013_bib0050","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.euf.2020.06.013_bib0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.urology.2019.08.054","article-title":"Predictors of poor response and adverse events following botulinum toxin-A for refractory idiopathic overactive bladder","volume":"135","author":"Abrar","year":"2020","journal-title":"Urology"},{"key":"10.1016\/j.euf.2020.06.013_bib0060","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/328364","article-title":"Predictors of response to intradetrusor botulinum toxin-A injections in patients with idiopathic overactive bladder","volume":"2009","author":"Cohen","year":"2009","journal-title":"Adv Urol"},{"key":"10.1016\/j.euf.2020.06.013_bib0065","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.juro.2017.04.103","article-title":"Characteristics associated with treatment response and satisfaction in women undergoing onabotulinumtoxinA and sacral neuromodulation for refractory urgency urinary incontinence","volume":"198","author":"Richter","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2020.06.013_bib0070","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.juro.2012.11.089","article-title":"Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity","volume":"189","author":"Liao","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2020.06.013_bib0075","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.urology.2007.11.039","article-title":"Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder","volume":"71","author":"Sahai","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.euf.2020.06.013_bib0080","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/JU.0000000000000525","article-title":"Treatment response and complications after intradetrusor onabotulinumtoxinA injection in male patients with idiopathic overactive bladder syndrome","volume":"203","author":"Mateu Arrom","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2020.06.013_bib0085","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0022-5347(06)00590-8","article-title":"Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics","volume":"176","author":"Schmid","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2020.06.013_bib0090","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00192-016-3212-4","article-title":"Urinary retention in female OAB after intravesical Botox injection: who is really at risk?","volume":"28","author":"Miotla","year":"2017","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.euf.2020.06.013_bib0095","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.eururo.2010.09.007","article-title":"Adverse events of intravesical botulinum toxin A injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome","volume":"58","author":"Kuo","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2020.06.013_bib0100","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/nau.22642","article-title":"Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome","volume":"34","author":"Osborn","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2020.06.013_bib0105","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1464-410X.2008.08076.x","article-title":"Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?","volume":"103","author":"Sahai","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2020.06.013_bib0110","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/nau.22494","article-title":"Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxinA injection in patients with refractory detrusor overactivity","volume":"33","author":"Wang","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2020.06.013_bib0115","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.eururo.2007.12.029","article-title":"Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity","volume":"54","author":"Kalsi","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2020.06.013_bib0120","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1471-0528.2004.00129.x","article-title":"How much is enough and who says so?","volume":"111","author":"Kelleher","year":"2004","journal-title":"BJOG"},{"key":"10.1016\/j.euf.2020.06.013_bib0125","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/nau.21021","article-title":"Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder","volume":"30","author":"Rovner","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2020.06.013_bib0130","doi-asserted-by":"crossref","first-page":"e886","DOI":"10.1016\/j.juro.2014.02.2405","article-title":"MP76-12 Overactive bladder patients \u226565 years of age have a similar efficacy and safety profile with onabotulinumtoxinA as patients <65 years of age","volume":"191","author":"Moore","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2020.06.013_bib0135","series-title":"OnabotulinumtoxinA demonstrates similar improvements in urinary incontinence and quality of life regardless of the use of clean intermittent catheterization or the presence of urinary tract infection in patients with overactive bladder","year":"2014"},{"key":"10.1016\/j.euf.2020.06.013_bib0140","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1464-410X.2009.08402.x","article-title":"Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial","volume":"103","author":"Sahai","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2020.06.013_bib0145","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.urology.2018.09.016","article-title":"Onabotulinum toxin A injections in men with refractory idiopathic detrusor overactivity","volume":"123","author":"Faure Walker","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.euf.2020.06.013_bib0150","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.juro.2007.01.130","article-title":"Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial","volume":"177","author":"Sahai","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2020.06.013_bib0155","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/nau.22948","article-title":"Patient factors associated with onabotulinum toxin A treatment outcome in women with detrusor overactivity","volume":"36","author":"Owen","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2020.06.013_bib0160","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1080\/03007995.2018.1443061","article-title":"Clean intermittent catheterization rates after initial and subsequent treatments with onabotulinumtoxinA for non-neurogenic overactive bladder in real-world clinical settings","volume":"34","author":"Kennelly","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.euf.2020.06.013_bib0165","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/SPV.0000000000000496","article-title":"Real-world retention rates after intravesical onabotulinumtoxinA for idiopathic overactive bladder","volume":"24","author":"Liberman","year":"2018","journal-title":"Female Pelvic Med Reconstr Surg"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456920301711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456920301711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:52:03Z","timestamp":1762498323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456920301711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2405456920301711"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2020.06.013","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2020.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}